The emergence of more infectious variants of the Covid-19 virus is threatening to slow the global recovery and potentially thwart current vaccine immunity. To help governments and medical communities identify and act on these variants faster, Oxford University and Oracle have created a Global Pathogen Analysis System (GPAS) combining Oxford’s Scalable Pathogen Pipeline Platform (SP3) with the power of Oracle Cloud Infrastructure (OCI).
This initiative builds on the work of a Wellcome Trust-funded consortium including Public Health Wales, the University of Cardiff and Public Health England.
“This powerful new tool will enable public health scientists in research establishments, public health agencies, healthcare services and diagnostic companies around the world to help further understanding of infectious diseases, starting with the coronavirus,” said Derrick Crook, Professor, Microbiology, Nuffield Department Medicine, University of Oxford.
“The Global Pathogen Analysis System will help to establish a global common standard for assembling and analyzing this new virus, as well as other microbial threats to public health. This adds a new dimension in our ability to process pathogen data. We are excited to partner with Oracle to further our research using this cutting-edge technology platform,” added Crook.
“The opportunity of applying systematic examination for genetic variants in a range of pathogens will have major benefits for global public health. This program, with Oracle as a partner, takes us a step closer to this goal,” said Sir John Bell, Regius Professor, Medicine, Oxford University.
Coupled with the extensive machine learning capabilities in the Oracle Cloud, collaborating scientists, researchers and governments worldwide can process, analyse, visualise and act on a wide collection of Covid-19 pathogen data for the first time. This includes identifying variants of interest and their potential impact on vaccine and treatment effectiveness. For example, analytics dashboards in the system will show which specific strains are spreading more quickly than others and whether genetic features contribute to increased transmissibility and vaccine escape. Already, Oxford has processed half the world’s SARS-CoV-2 sequences, more than 500,000 in total.
“There is a critical need for global cooperation on genomic sequencing and examination of Covid-19 and other pathogens,” said Chairman and CTO, Larry Ellison, Oracle.
The next step will be to extend this service to all pathogens while simultaneously collaborating with scientists from research establishments, public health agencies and private companies to ensure this work can inform decision making on pandemic response strategies worldwide. The platform will be free for researchers and non-profits to use worldwide.
“The SP3 platform has come out of engagement, design and testing activities that have been running over the past several years through close collaboration between researchers at Cardiff University and the University of Oxford, Public Health England and the European Bioinformatics Institute, along with other stakeholders from public health in the UK. This new Global Pathogen Analysis System will enable collaborating scientists to analyse a pool of worldwide data in new ways, providing better intelligence on virus variants of concern and their potential for spread,” said Professor Thomas R Connor, School of Bioscience, Cardiff University.
Dr. Isabel Oliver, Director, National Infection Service, Public Health England noted, “This donation is a welcome boost to the ability to share genomic sequencing data with colleagues all across the world. Not only are strong genomic examination and widely-available data crucial to our collective efforts to combat the current pandemic, but they will have ongoing benefits to the response to other pathogens in the future. This could potentially have a far-reaching positive impact on international public health and global health security. As new variants of SARS-CoV-2 emerge around the world, it requires a cooperative global effort to respond effectively.”
If you have an interesting article / experience / case study to share, please get in touch with us at email@example.com